Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer

The authors performed a dose escalation study of cisplatin and the novel deoxycytidine analog, tezacitabine, to determine the maximum tolerated dose of the combination.

[1]  Peng Huang,et al.  Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event , 2004, Cancer Chemotherapy and Pharmacology.

[2]  T. Thigpen.  The role of gemcitabine-based doublets in the management of ovarian carcinoma. , 2002, Seminars in oncology.

[3]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[4]  W. Plunkett,et al.  Action of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response. , 2002, Molecular pharmacology.

[5]  G. Sanguineti,et al.  Gemcitabine, Cisplatin, and Radiation in Advanced, Unresectable Squamous Cell Carcinoma of the Head and Neck: A Feasibility Study , 2001, American journal of clinical oncology.

[6]  P. Philip,et al.  Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma , 2001, Cancer.

[7]  A. Mohar,et al.  A phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  R. Nagourney.  Gemcitabine plus cisplatin in breast cancer. , 2001, Oncology.

[9]  K. Seley.  Tezacitabine Hoechst Marion Roussel. , 2000, Current opinion in investigational drugs.

[10]  R. Kotchetkov,et al.  Selective cytotoxic activity of a novel ribonucleoside diphosphate reductase inhibitor MDL-101,731 against thyroid cancer in vitro. , 1999, Folia biologica.

[11]  L. Guillou,et al.  (E)-2'-deoxy-2'-(fluoromethylene) cytidine potentiates radioresponse of two human solid tumor xenografts. , 1998, Cancer research.

[12]  S. Akinaga,et al.  Metabolism and ribonucleotide reductase inhibition of (E  )-2′-deoxy-2′-(fluoromethylene)cytidine, MDL 101,731, in human cervical carcinoma HeLa S3 cells , 1998, Cancer Chemotherapy and Pharmacology.

[13]  R. Mirimanoff,et al.  Antitumor and radiosensitizing effects of (E)-2'-deoxy-2'-(fluoromethylene) cytidine, a novel inhibitor of ribonucleoside diphosphate reductase, on human colon carcinoma xenografts in nude mice. , 1997, Cancer research.

[14]  A. Bitonti,et al.  In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor. , 1996, Cancer research.

[15]  Bushueva Tl,et al.  Response of human colon and prostate tumor xenografts to (E)-2'-deoxy-2'-(fluoromethylene) cytidine, an inhibitor of ribonucleotide reductase. , 1995 .

[16]  A. Bitonti,et al.  Response of human colon and prostate tumor xenografts to (E)-2'-deoxy-2'-(fluoromethylene) cytidine, an inhibitor of ribonucleotide reductase. , 1995, Anticancer research.

[17]  A. Bitonti,et al.  Regression of human breast tumor xenografts in response to (E)-2'-deoxy-2'-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase. , 1994, Cancer research.

[18]  S. Rd.  Effect of 2'-deoxy-2'-(fluoromethylene) cytidine on the ultraviolet and X-ray sensitivity of HeLa cells. , 1994 .

[19]  R. Snyder.  Effect of 2'-deoxy-2'-(fluoromethylene) cytidine on the ultraviolet and X-ray sensitivity of HeLa cells. , 1994, Oncology research.

[20]  D. Stemerick,et al.  Stereospecific method to (E) and (Z) terminal fluoroolefins and its application to the synthesis of 2'-deoxy-2'-fluoromethylenenucleosides as potential inhibitors of ribonucleoside diphosphate reductase , 1991 .

[21]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[22]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.